ReviewNature clinical practice. Oncology2009
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
Review in Nature clinical practice. Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.Chinese journal of cancer · 2011Trial
- Integration of continuous lumbar drainage and third-generation EGFR-TKI in managing leptomeningeal metastasis-induced life-threatening intracranial hypertension: a case report.Frontiers in oncology · 2025Article
- Article
- Neuraxis Metastases Of Primary Central Nervous System Tumors: A Review Of Clinicopathological And Radiographic Characters Of 198 Cases In A Single Center.Cancer management and research · 2019Article
- Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.Stem cells (Dayton, Ohio) · 2015Article
- Design, synthesis, and characterization of graphene-nanoparticle hybrid materials for bioapplications.Chemical reviews · 2015Review
- Prospects for graphene-nanoparticle-based hybrid sensors.Physical chemistry chemical physics : PCCP · 2013Article
- Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.Cancer treatment reviews · 2013Review
- Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment.Journal of neuro-oncology · 2012Article
- Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.Oncotarget · 2011Article
- Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death.BMC cancer · 2011Article
- Detection of cancer cells in the cerebrospinal fluid: current methods and future directions.Fluids and barriers of the CNS · 2011Article
- Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.Therapeutic delivery · 2010Review
- Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.PloS one · 2009Article
- Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Prognostic scores in brain metastases from breast cancer.BMC cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of trastuzumab for the treatment of tumors that overexpress ErbB2 (also known as HER2) has contributed significantly to recent improvements in systemic therapy for advanced breast cancer. The advances in systemic therapy have highlighted an increasing prevalence of central nervous system involvement in patients with ErbB2-positive breast cancer and a consequent need for new treatment options for brain metastases. Just as ErbB2-targeted systemic therapy has given rise to this challenge, so too could targeted therapy represent an opportunity to meet it. This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.